Latest Updates

Lonza Reports Strong 2020 Performance, Driven By Sales Growth in Pharma and Biotech Business

Lonza (with the Specialty Ingredients segment – LSI – reported as discontinued operations) today reported strong sales of CHF 4.5 billion, sales growth of 12.0%5, and CHF 1.4 billion CORE EBITDA, resulting in a margin of 31.2%. The results mainly reflect the Pharma Biotech & Nutrition segment (LPBN), which delivered 12.2%5 sales growth and a CORE EBITDA margin of 32.1%.

January 27, 2021

SOCMA Policy Blog

SOCMA has identified two EOs that will intersect with the work and activities of its Environmental, Health and Safety committee. Alongside our members, we are prepared to further our advocacy efforts through each agency's review and decision process.

January 27, 2021

SOCMA Congratulates Biden Administration on Inauguration

Jennifer Abril, President & CEO of the Society of Chemical Manufacturers & Affiliates (SOCMA), released a statement today in response to the inauguration of President Joseph R. Biden Jr. and Vice President Kamala Harris.

January 20, 2021

SOCMA Welcomes Three New Member Companies to Begin 2021

The Society of Chemical Manufacturers & Affiliates (SOCMA) is pleased to announce the addition of three companies – Valysynthese, Gold Eagle and Forever Pumpkin – to its growing and diverse membership. This brings SOCMA’s total membership to 135 companies to commence 2021.

January 14, 2021

Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics for the treatment and prevention of serious diseases, and Lonza today announced that the companies have entered into an agreement for the development of CAP-1002, Capricor's leading clinical asset using allogeneic cardiosphere-derived cells (CDC) technology for the treatment of Duchenne Muscular Dystrophy (DMD) and complications arising from COVID-19.

January 12, 2021